China Becomes First Nation to Approve Brain-Computer Interface Device for Sale

Chinese regulators have granted the world's first commercial approval for a brain-computer interface system that helps paralyzed patients regain hand movement. The device, made by a Shanghai-based company, uses wireless technology and electrodes implanted in the brain to control a special glove.

Chinese medical regulators made history Friday by becoming the first in the world to authorize commercial sales of a brain-computer interface system designed to help paralyzed individuals regain hand function.

The groundbreaking device, developed by Shanghai-based Borui Kang Medical Technology, represents a major milestone in neurotechnology aimed at restoring movement and communication capabilities for people living with various forms of paralysis.

Specifically engineered for individuals with quadriplegia resulting from cervical spinal cord damage, the system enables patients to regain their ability to grasp objects through the use of a specialized glove.

The technology operates as an invasive brain-computer interface, meaning electrodes are surgically placed directly into brain tissue rather than positioned on the brain’s surface. The system utilizes minimally invasive surgical techniques for electrode placement outside the brain’s protective covering and relies on wireless communication technology.

According to China’s National Medical Products Administration, brain-computer interface technologies like this newly approved device have received priority status from the government. Officials noted that Beijing has classified this sector as a “future industry” in the country’s most recent five-year development plan announced last week.

A prominent expert in brain-computer interface technology told Reuters recently that China could witness these systems entering widespread public application within the next three to five years as the technology advances. This development comes as Beijing works to compete with American companies in the field, including Elon Musk’s Neuralink venture.

The approved device has specific patient requirements for eligibility. Candidates must be between 18 and 60 years old and have sustained a particular type of spinal cord injury. Their medical diagnosis must be at least one year old, and they must maintain stable health for six months after receiving standard medical treatment. Qualifying patients cannot grasp with their hands but must still have some functioning in their upper arms.

Regulatory officials reported that clinical testing demonstrated notable improvements in participants’ hand-grasping capabilities. The agency stated these enhancements contributed to better overall quality of life for patients involved in the trials.